Cargando…
Use of Recombinant Zoster Vaccine in Immunocompromised Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices — United States, 2022
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Centers for Disease Control and Prevention
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8774159/ https://www.ncbi.nlm.nih.gov/pubmed/35051134 http://dx.doi.org/10.15585/mmwr.mm7103a2 |
| _version_ | 1784636269682229248 |
|---|---|
| author | Anderson, Tara C. Masters, Nina B. Guo, Angela Shepersky, Leah Leidner, Andrew J. Lee, Grace M. Kotton, Camille N. Dooling, Kathleen L. |
| author_facet | Anderson, Tara C. Masters, Nina B. Guo, Angela Shepersky, Leah Leidner, Andrew J. Lee, Grace M. Kotton, Camille N. Dooling, Kathleen L. |
| author_sort | Anderson, Tara C. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8774159 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Centers for Disease Control and Prevention |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-87741592022-01-28 Use of Recombinant Zoster Vaccine in Immunocompromised Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices — United States, 2022 Anderson, Tara C. Masters, Nina B. Guo, Angela Shepersky, Leah Leidner, Andrew J. Lee, Grace M. Kotton, Camille N. Dooling, Kathleen L. MMWR Morb Mortal Wkly Rep Full Report Centers for Disease Control and Prevention 2022-01-21 /pmc/articles/PMC8774159/ /pubmed/35051134 http://dx.doi.org/10.15585/mmwr.mm7103a2 Text en https://creativecommons.org/publicdomain/zero/1.0/All material in the MMWR Series is in the public domain and may be used and reprinted without permission; citation as to source, however, is appreciated. |
| spellingShingle | Full Report Anderson, Tara C. Masters, Nina B. Guo, Angela Shepersky, Leah Leidner, Andrew J. Lee, Grace M. Kotton, Camille N. Dooling, Kathleen L. Use of Recombinant Zoster Vaccine in Immunocompromised Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices — United States, 2022 |
| title | Use of Recombinant Zoster Vaccine in Immunocompromised Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices — United States, 2022 |
| title_full | Use of Recombinant Zoster Vaccine in Immunocompromised Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices — United States, 2022 |
| title_fullStr | Use of Recombinant Zoster Vaccine in Immunocompromised Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices — United States, 2022 |
| title_full_unstemmed | Use of Recombinant Zoster Vaccine in Immunocompromised Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices — United States, 2022 |
| title_short | Use of Recombinant Zoster Vaccine in Immunocompromised Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices — United States, 2022 |
| title_sort | use of recombinant zoster vaccine in immunocompromised adults aged ≥19 years: recommendations of the advisory committee on immunization practices — united states, 2022 |
| topic | Full Report |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8774159/ https://www.ncbi.nlm.nih.gov/pubmed/35051134 http://dx.doi.org/10.15585/mmwr.mm7103a2 |
| work_keys_str_mv | AT andersontarac useofrecombinantzostervaccineinimmunocompromisedadultsaged19yearsrecommendationsoftheadvisorycommitteeonimmunizationpracticesunitedstates2022 AT mastersninab useofrecombinantzostervaccineinimmunocompromisedadultsaged19yearsrecommendationsoftheadvisorycommitteeonimmunizationpracticesunitedstates2022 AT guoangela useofrecombinantzostervaccineinimmunocompromisedadultsaged19yearsrecommendationsoftheadvisorycommitteeonimmunizationpracticesunitedstates2022 AT sheperskyleah useofrecombinantzostervaccineinimmunocompromisedadultsaged19yearsrecommendationsoftheadvisorycommitteeonimmunizationpracticesunitedstates2022 AT leidnerandrewj useofrecombinantzostervaccineinimmunocompromisedadultsaged19yearsrecommendationsoftheadvisorycommitteeonimmunizationpracticesunitedstates2022 AT leegracem useofrecombinantzostervaccineinimmunocompromisedadultsaged19yearsrecommendationsoftheadvisorycommitteeonimmunizationpracticesunitedstates2022 AT kottoncamillen useofrecombinantzostervaccineinimmunocompromisedadultsaged19yearsrecommendationsoftheadvisorycommitteeonimmunizationpracticesunitedstates2022 AT doolingkathleenl useofrecombinantzostervaccineinimmunocompromisedadultsaged19yearsrecommendationsoftheadvisorycommitteeonimmunizationpracticesunitedstates2022 |